{"id":781845,"date":"2023-09-05T09:40:13","date_gmt":"2023-09-05T13:40:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/"},"modified":"2023-09-05T09:40:13","modified_gmt":"2023-09-05T13:40:13","slug":"ikena-oncology-to-participate-in-september-2023-investor-conferences","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/","title":{"rendered":"Ikena Oncology to Participate in September 2023 Investor Conferences"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">BOSTON, Sept.  05, 2023  (GLOBE NEWSWIRE) &#8212; Ikena Oncology, Inc. (Nasdaq: IKNA, \u201cIkena,\u201d \u201cCompany\u201d), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY.<\/p>\n<p>Details are as follows:<\/p>\n<p>\n        <strong>Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023<\/strong><br \/>\n        <br \/>One-on-One Investor Meetings September 11, 2023<br \/>Fireside Chat: Monday, September 11, 2023, at 3:35pm ET<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=S7OJTAbYhK9JgHnEBQoJTUP08MLqEIumzwxzLg9mTbLWFk6fXVILr5K0cCtLb4Ews-AtSWEb3dpq19DYvHjq-VGQQNATpv73f1FTO-P1K4gBOXzhjUQCSHMsQDuLY3AV4CZFYL7JUDc6ikZIscmscyifZj9vPdk9Ov87-meagJo=\" rel=\"nofollow noopener\" target=\"_blank\">Webcast Link<\/a><\/p>\n<p>\n        <strong>H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023<\/strong><br \/>\n        <br \/>One-on-One Investor Meetings September 13, 2023<\/p>\n<p>The fireside chat webcast will be available on the Company\u2019s Events &amp; Presentations page on their website at <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-GZ3mmKW29yVmUskdVAnvTUop5KDqN-SNoSTMWeL9CQa4VZT65vdIk2LqkRpuOCdhnEgBlQR775NcMxJhM5woqZi8kaR_UtUmLrLFuJi-Z0=\" rel=\"nofollow noopener\" target=\"_blank\">www.ikenaoncology.com<\/a>. The webcast will be archived for a period of 90 days following the conclusion of the live event.<\/p>\n<p>\n        <strong>About Ikena Oncology<\/strong><br \/>\n        <br \/>Ikena Oncology<sup>\u00ae<\/sup> is focused on developing differentiated therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. The Company\u2019s lead targeted oncology program, IK-930, is a TEAD1 selective Hippo pathway inhibitor, a known tumor suppressor pathway that also drives resistance to multiple targeted therapies. The Company\u2019s additional research spans other targets in the Hippo pathway as well as the RAS signaling pathway, including developing IK-595, a novel MEK-RAF inhibitor. Additionally, IK-175, an AHR antagonist, is being developed in collaboration with Bristol Myers Squibb. Ikena aims to utilize their depth of institutional knowledge and breadth of tools to efficiently develop the right drug using the right modality for the right patient. To learn more, visit www.ikenaoncology.com or follow us on Twitter and LinkedIn.<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong><br \/>\n        <br \/>This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, implied and express statements regarding: projected cash runway; the anticipated use of proceeds from the underwritten registered offering and Pionyr acquisition, the timing and advancement of our targeted oncology programs, including the timing of updates; our expectations regarding the therapeutic benefit of our targeted oncology programs; our ability to efficiently discover and develop product candidates; our ability to obtain and maintain regulatory approval of our product candidates; the implementation of our business model, expectations with respect to cash runway, and strategic plans for our business and product candidates. The words \u201cmay,\u201d \u201cwill,\u201d \u201ccould,\u201d \u201cwould,\u201d \u201cshould,\u201d \u201cexpect,\u201d \u201cplan,\u201d \u201canticipate,\u201d \u201cintend,\u201d \u201cbelieve,\u201d \u201cestimate,\u201d \u201cpredict,\u201d \u201cproject,\u201d \u201cpotential,\u201d \u201ccontinue,\u201d \u201ctarget\u201d and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management\u2019s current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, those risks and uncertainties related to the timing and advancement of our targeted oncology programs; our expectations regarding the therapeutic benefit of our targeted oncology programs; our ability to efficiently discover and develop product candidates; the implementation of our business model, and strategic plans for our business and product candidates, the sufficiency of the Company\u2019s capital resources to fund operating expenses and capital expenditure requirements and the period in which such resources are expected to be available, and other factors discussed in the \u201cRisk Factors\u201d section of Ikena\u2019s Quarterly Report on Form 10-Q for the quarter ended June 30, 2023, which is on file with the SEC, as updated by any subsequent SEC filings. We caution you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. We disclaim any obligation to publicly update or revise any such statements to reflect any change in expectations or in events, conditions or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. Any forward-looking statements contained in this press release represent our views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. We explicitly disclaim any obligation to update any forward-looking statements.<\/p>\n<p><strong>Investor Contact:<\/strong><br \/>Rebecca Cohen<br \/>Ikena Oncology<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9IiprraYL3H0qZFt47QwHSAru0rI9qgG9Fv_dV0d6K2OFcctC1OzqWNNAKVdgRjYwWjIpC1bC4mVQajB4ir4rmiAEZYi7zh_vVDrdxM0tns=\" rel=\"nofollow noopener\" target=\"_blank\">rcohen@ikenaoncology.com<\/a>\u00a0\u00a0<\/p>\n<p>\n        <strong>Media Contact:<\/strong><br \/>\n        <br \/>Luke Shiplo<br \/>LifeSci Communications<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=-Woef9sEPJLHdRMl5M8QUGgN0Je_kBnYNPU30c3nOoKHnNqwNbe7vD9_y_2FCIdyEZS7ZuhQ1wrwU5jaQCAWtiRmzH0ZWHY6dCR6sxFRXmI=\" rel=\"nofollow noopener\" target=\"_blank\">lshiplo@lifescicomms.com<\/a><\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/OTljNDJiOWMtZGUzYi00Nzc0LThlZDgtOWEyZDhlZWI0MGQ1LTEyMTc0Mjk=\/tiny\/Ikena-Oncology-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) &#8212; Ikena Oncology, Inc. (Nasdaq: IKNA, \u201cIkena,\u201d \u201cCompany\u201d), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023 One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebcast Link H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023 One-on-One Investor Meetings September 13, 2023 The fireside chat webcast will be available on the Company\u2019s Events &amp; Presentations page on their website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Ikena Oncology to Participate in September 2023 Investor Conferences&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-781845","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) &#8212; Ikena Oncology, Inc. (Nasdaq: IKNA, \u201cIkena,\u201d \u201cCompany\u201d), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023 One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebcast Link H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023 One-on-One Investor Meetings September 13, 2023 The fireside chat webcast will be available on the Company\u2019s Events &amp; Presentations page on their website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the &hellip; Continue reading &quot;Ikena Oncology to Participate in September 2023 Investor Conferences&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-05T13:40:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Ikena Oncology to Participate in September 2023 Investor Conferences\",\"datePublished\":\"2023-09-05T13:40:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/\"},\"wordCount\":714,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/\",\"name\":\"Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\",\"datePublished\":\"2023-09-05T13:40:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/ikena-oncology-to-participate-in-september-2023-investor-conferences\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ikena Oncology to Participate in September 2023 Investor Conferences\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/","og_locale":"en_US","og_type":"article","og_title":"Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk","og_description":"BOSTON, Sept. 05, 2023 (GLOBE NEWSWIRE) &#8212; Ikena Oncology, Inc. (Nasdaq: IKNA, \u201cIkena,\u201d \u201cCompany\u201d), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that management will participate in two upcoming investor conferences in New York, NY. Details are as follows: Morgan Stanley 21st Annual Global Healthcare Conference, September 11-13, 2023 One-on-One Investor Meetings September 11, 2023Fireside Chat: Monday, September 11, 2023, at 3:35pm ETWebcast Link H.C. Wainwright 25th Annual Global Investment Conference, September 11-13, 2023 One-on-One Investor Meetings September 13, 2023 The fireside chat webcast will be available on the Company\u2019s Events &amp; Presentations page on their website at www.ikenaoncology.com. The webcast will be archived for a period of 90 days following the conclusion of the &hellip; Continue reading \"Ikena Oncology to Participate in September 2023 Investor Conferences\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-05T13:40:13+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Ikena Oncology to Participate in September 2023 Investor Conferences","datePublished":"2023-09-05T13:40:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/"},"wordCount":714,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/","name":"Ikena Oncology to Participate in September 2023 Investor Conferences - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=","datePublished":"2023-09-05T13:40:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODkxNTQzMiM1Nzk1MjgzIzIyMDU4NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/ikena-oncology-to-participate-in-september-2023-investor-conferences\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Ikena Oncology to Participate in September 2023 Investor Conferences"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781845","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=781845"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/781845\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=781845"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=781845"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=781845"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}